Results 241 to 250 of about 477,437 (308)

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

open access: yes
The Laryngoscope, EarlyView.
Alina Zgardau   +3 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

open access: yes
The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart   +3 more
wiley   +1 more source

Role of Acid‐Sensing Ion Channels 1a in the Regulation of Obesity and the Gut Microbiota

open access: yesObesity, EarlyView.
ABSTRACT Objective Acid‐sensing ion channels are proton‐activated ion channels predominantly found in the nervous system. They are well known to affect metabolic and neurological health, yet their role in obesity and gut physiology remains unclear. This study investigates how systemic deletion of Asic1a influences obesity, metabolic, and gut‐based ...
Jane Shearer   +7 more
wiley   +1 more source

Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice

open access: yesObesity, EarlyView.
ABSTRACT Objective In this study, we investigated the effects of a stem cell‐derived secretome product on adiposity and tissue quality and insulin and glucose levels in obese mice and those undergoing dietary weight loss. Methods Following 16 weeks of high fat diet mice received acute (4 weeks) biweekly intramuscular injections with vehicle or ...
Zachary J. Fennel   +11 more
wiley   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

open access: yesObesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi   +5 more
wiley   +1 more source

Examining Biomarkers for Dyslipidemia, Diabetes, and NAFLD by CDC's 2022 Extended BMI Percentiles in US Youth Aged 6–17 Years

open access: yesObesity, EarlyView.
ABSTRACT Objective This study examined associations between CDC's 2022 extended BMI percentiles (BMIp) and cardiometabolic biomarkers. Methods Using electronic medical record data, we included patients aged 6–17 years with BMI ≥ 85th percentile who had at least one of the following: total cholesterol, low‐density lipoprotein cholesterol (LDL), high ...
Samantha L. Pierce   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy